Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Highlights to be presented at Novo Nordisk's Capital Markets Day 2017 | ||||||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 21 Nov 2017 | Back to overview list |
|||||||||||||||||||||||||||||||
Bagsværd, Denmark, 21 November 2017 - Novo Nordisk will today host a Capital Markets Day where the company will provide updates on its R&D and commercial strategy as well as current market dynamics. Novo Nordisk's ambition is to further expand its leadership in the global diabetes and obesity care markets by discovering, developing and marketing improved insulin and GLP-1 analogues as well as completely new classes of biologics. Furthermore, it is Novo Nordisk's ambition to return to growth in the Biopharm area. The key topics of the day will be:
In addition, the Capital Markets Day 2017 will include break-out sessions covering oral semaglutide and the associated production expansion, the regions in International Operations: Region China and Region AAMEO (Africa, Asia, Middle-East Oceania) as well as an update on the business dynamics in Biopharm Operations.
NOVO NORDISK'S R&D STRATEGY AND KEY DEVELOPMENT PROJECTS
NOVO NORDISK'S COMMERCIAL PRIORITIES WITHIN DIABETES CARE
NOVO NORDISK'S AMBITION TO EXPAND THE GLOBAL OBESITY MARKET
Following the positive clinical phase 2 results with subcutaneous semaglutide in obesity, Novo Nordisk plans to initiate a phase 3a clinical development, STEP, with once-weekly subcutaneous semaglutide in 2018. The global clinical programme is expected to enrol approximately 4,500 people with obesity and all main trials within the programme will have a duration of 68 weeks. In addition to the phase 3a programme, STEP, Novo Nordisk is also planning to initiate a landmark cardiovascular outcome trial in 2018 with once-weekly subcutaneous semaglutide in obesity with an expected enrolment of approximately 12,500 people.
MARKET DYNAMICS IN INTERNATIONAL OPERATIONS AND THE USA
WEB CAST DETAILS All main sessions of the Capital Markets Day 2017 will be webcast live, and a replay will be made available on the investor section of novonordisk.com. Presentation material for the Capital Markets Day 2017 will be available 21 November at approximately 8.30 am CET, corresponding to 2.30 am EST on the investor section of novonordisk.com. Further information
Company announcement No 87 / 2017
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novo Nordisk A/S via GlobeNewswire
HUG#2150981
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |